Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534806 | 1.00 | REN (0.85) | REN | |
| SCHEMBL8784488 | 0.92 | REN (1.00) | REN | |
| SCHEMBL5730466 | 0.90 | REN (0.70) | REN | |
| SCHEMBL4047197 | 0.89 | REN (0.72) | REN | |
| SCHEMBL4039523 | 0.88 | REN (0.72) | REN | |
| SCHEMBL4340273 | 0.86 | REN (0.82) | REN | |
| SCHEMBL4041807 | 0.85 | REN (0.62) | REN | |
| SCHEMBL4043497 | 0.84 | REN (0.65) | REN | |
| SCHEMBL4043571 | 0.84 | REN (0.63) | REN | |
| SCHEMBL8498476 | 0.83 | LAP3 (0.71) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655686-B2 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-7612054-B2 | Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| WO-2009013293-A1 | SUBSTITUTED CYCLOHEXANECARBOXAMIDES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| EP-1670803-B1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070265328-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2007-05-17 | — | — | US | disclosed |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | AUBERSON YVES | 2007-01-18 | — | — | US | disclosed |
| EP-1670803-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | Novartis AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005035535-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265328-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | STS, RPS6KA5, RPIA | REN 46/4885 |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | STS, RPS6KA5, RPIA | REN 46/4885 |
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | APP, BACE1, BCHE | REN 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.